Neogenomics (NEO) Income from Continuing Operations (2010 - 2026)

Neogenomics (NEO) has 17 years of Income from Continuing Operations data on file, last reported at 2238000.0 in Q2 2026.

• Quarterly Income from Continuing Operations rose 104.96% year-over-year to 2238000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 51878000.0 (up 50.14% YoY) and the FY2025 annual result came in at 108025000.0, down 37.22% from the prior year.
• Income from Continuing Operations climbed to 2238000.0 in Q2 2026, from 17106000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 2238000.0 in Q2 2026 to a low of 49408000.0 in Q1 2022.
• A 5-year average of 24102055.56 and a median of 23509000.0 in 2022 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 146.53% — and 2026, when it jumped 104.96%.
• Tracing NEO's Income from Continuing Operations over 5 years: stood at 22687000.0 in 2022, then jumped by 36.85% to 14326000.0 in 2023, then decreased by 6.97% to 15324000.0 in 2024, then soared by 35.52% to 9881000.0 in 2025, then surged by 122.65% to 2238000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2238000.0 (Q2 2026), 17106000.0 (Q1 2026), and 9881000.0 (Q4 2025), per Business Quant data.